22 March 2013
Treatment of Cytomegalovirus infection after renal transplantation: Experience from a Single Center in China
Yang LiABCDEFG, Hang YanACFG, Wu-Jun XueABCDG, Pu-Xun TianACF, Xiao-Ming DingACF, Xiao-Ming PanACF, Xin-Shun FengACF, He-Li XiangACF, Jun HouACF, Xiao-Hui TianACF, Jin ZhengCF, Chen-Guang DingCF, Ping FanCEFG, Hong-Bao LiuCFDOI: 10.12659/AOT.883859
Ann Transplant 2013; 18:124-134
Abstract
BACKGROUND: We compared the efficacy and safety of 2 different treatments of CMV infection, including asymptomatic CMV replication and CMV disease.
MATERIAL AND METHODS: 852 renal transplantation recipients, including asymptomatic CMV replication and CMV disease, received antiviral therapies of intravenous acyclovir or comprehensive anti-infection solution, mainly with intravenous ganciclovir. Effect, time, acute allograft rejection, and safety were analyzed during the antiviral therapy
RESULTS: The total effective rates were higher with ganciclovir in both asymptomatic CMV replication (98.96% vs. 84.90%) and CMV disease (96.29% vs. 50.36%). Ganciclovir significantly shortened antiviral therapy duration in both asymptomatic CMV replication (15.0±2.3 days vs. 16.0±3.4 days) and CMV disease (19.7±3.1 days vs. 21.5±4.0 days). The acute allograft rejection incidences were significantly lower with ganciclovir in both asymptomatic CMV replication (8% vs. 14%) and CMV disease (11% vs. 22%). CMV-IEA was detected in renal grafts of patients with acute rejection. There was more CMV-associated acute rejection using acyclovir than using ganciclovir. Except for the higher incidence of anemia leucopenia and anemia with ganciclovir, the safety profiles of both drugs were similar.
CONCLUSIONS: Comprehensive anti-infection solution, mainly with intravenous ganciclovir, can effectively treat CMV infection, shorten duration of therapy, and decrease acute rejection. The few adverse effects had negligible effects on use of ganciclovir.
Keywords: Cytomegalovirus (CMV), renal transplantation, acyclovir, Ganciclovir
In Press
Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...Ann Transplant In Press; DOI: 10.12659/AOT.945249
Original article
Biopsychosocial Effects of Donor Traits on Heart Transplant RecipientsAnn Transplant In Press; DOI:
Clinical Research
Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...Ann Transplant In Press; DOI:
Original article
Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...Ann Transplant In Press; DOI: 10.12659/AOT.944320
Most Viewed Current Articles
05 Apr 2022 : Original article 13,113
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,260
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,611
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,271
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860